<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Bacterial vaginosis: Initial treatment
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Bacterial vaginosis: Initial treatment
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Bacterial vaginosis: Initial treatment
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jack D Sobel, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeanne Marrazzo, MD, MPH, FACP, FIDSA
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert L Barbieri, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kristen Eckler, MD, FACOG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 12, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H883139068">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bacterial vaginosis (BV) is the most common cause of abnormal vaginal discharge in reproductive-age females. Treatment is aimed at relieving symptoms, although many individuals are asymptomatic. Of those with symptoms, abnormal vaginal discharge and fishy odor are typical.
        </p>
        <p>
         This topic will present the treatment options for various groups of patients with BV. Related topics on the presentation and diagnosis of BV and management of patients with recurrent BV, as well as the approach to the individual with vaginal discharge or cervicitis, are presented separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5451.html" rel="external">
          "Bacterial vaginosis: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/131928.html" rel="external">
          "Bacterial vaginosis: Recurrent infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5477.html" rel="external">
          "Vaginitis in adults: Initial evaluation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5460.html" rel="external">
          "Acute cervicitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         In this topic, when discussing study results, we will use the terms "women" or "patients" as they are used in the studies presented. We encourage the reader to consider the specific counseling and treatment needs of transgender and gender-expansive individuals.
        </p>
        <p class="headingAnchor" id="H2649853388">
         <span class="h1">
          RATIONALE FOR TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with confirmed BV who are symptomatic or who are undergoing a gynecologic procedure involving the vagina (regardless of symptoms) are treated [
         <a href="#rid1">
          1,2
         </a>
         ]. Aside from those undergoing gynecologic surgery, we generally do not treat other asymptomatic individuals because BV is self-limiting in approximately one-third of nonpregnant persons and one-half of pregnant persons [
         <a href="#rid3">
          3-6
         </a>
         ]. (See
         <a class="local">
          'Individuals undergoing gynecologic procedures'
         </a>
         below.)
        </p>
        <p>
         Benefits of treatment include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Relief of symptoms
         </strong>
         (if present). (See
         <a class="medical medical_review" href="/z/d/html/5451.html" rel="external">
          "Bacterial vaginosis: Clinical manifestations and diagnosis", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reduction of postoperative infection
         </strong>
         – For individuals with asymptomatic infection prior to surgical abortion or hysterectomy, treatment can reduce the risk of postoperative infection. (See
         <a class="local">
          'Individuals undergoing gynecologic procedures'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reduction of sexually transmitted infections
         </strong>
         – Treatment of BV may reduce the risk of acquiring sexually transmitted infections (STIs), including HIV [
         <a href="#rid7">
          7,8
         </a>
         ]. For this reason, some experts support the concept of treating all patients with BV regardless of presence or absence of symptoms. However, we agree with recommendations to not treat asymptomatic individuals unless they are undergoing gynecologic surgery [
         <a href="#rid1">
          1,9
         </a>
         ]. Asymptomatic pregnant individuals with previous preterm births may benefit from treatment, but screening and treatment of these individuals has overall not been shown to be of benefit in averting adverse consequences of BV as it relates to pregnancy. (See
         <a class="local">
          'Asymptomatic pregnant persons'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1605681669">
         <span class="h1">
          DRUG DESCRIPTION AND SELECTION
         </span>
        </p>
        <p class="headingAnchor" id="H1169760929">
         <span class="h2">
          Metronidazole
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          Metronidazole
         </a>
         is given as an oral or vaginal medication over multiple days  (
         <a class="graphic graphic_table graphicRef77648" href="/z/d/graphic/77648.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef131909" href="/z/d/graphic/131909.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         – The choice of oral versus vaginal therapy depends upon patient preference because the efficacy is similar for multiday oral or vaginal treatments.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Oral pills
         </strong>
         – We suggest oral
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         500 mg twice daily for seven days [
         <a href="#rid1">
          1
         </a>
         ]. Treatment with a single oral dose of 2 grams of metronidazole has lower efficacy [
         <a href="#rid10">
          10
         </a>
         ] and thus is not recommended for treatment of BV.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Vaginal gel
         </strong>
         – Vaginal therapy is given as
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         0.75% gel; a 5-gram applicator is inserted into the vagina once daily for five days (5 grams of gel contains 37.5 mg of metronidazole) [
         <a href="#rid1">
          1,11,12
         </a>
         ]. The multiday vaginal gel has similar efficacy to seven days of oral metronidazole [
         <a href="#rid13">
          13-15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Single-dose treatment options
         </strong>
         – A newer single-dose
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         gel (1.3%) is available [
         <a href="#rid16">
          16
         </a>
         ]. While the single-dose 1.3% treatment is superior to placebo gel [
         <a href="#rid17">
          17
         </a>
         ], it is not known if the 1.3% single-day dose is as efficacious as the multiday oral or multiday 0.75% vaginal metronidazole treatments, and therefore we prefer the multiday treatments.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         As above, single-dose oral
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         is not advised because of lower efficacy compared with multiday dosing [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Common
         </strong>
         – Side effects of
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         (oral or vaginal) include a metallic taste, nausea (in 10 percent of patients), transient neutropenia (7.5 percent), prolongation of international normalized ratio in patients taking vitamin K antagonists (eg,
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         ), and peripheral neuropathy [
         <a href="#rid18">
          18
         </a>
         ]. Gastrointestinal side effects are less common with vaginal administration [
         <a href="#rid14">
          14
         </a>
         ]. Patients who are being treated with
         <a class="drug drug_general" data-topicid="9379" href="/z/d/drug information/9379.html" rel="external">
          disulfiram
         </a>
         should not use metronidazole as psychotic reactions have been reported [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Alcohol consumption
         </strong>
         – For patients receiving oral nitroimidazoles, manufacturer packaging advises abstaining from alcohol consumption during treatment and for 24 hours after treatment [
         <a href="#rid18">
          18
         </a>
         ]. However, data supporting this statement are sparse, and the magnitude of risk appears to be low [
         <a href="#rid19">
          19
         </a>
         ]. We do not counsel patients taking oral or vaginal
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         to avoid alcohol during treatment [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Drug allergy
         </strong>
         – Allergy to
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         is uncommon; it manifests as rash, urticaria, pruritus, and, rarely, anaphylaxis. The majority of patients can successfully undergo oral desensitization [
         <a href="#rid20">
          20,21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – The efficacy of
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         has been established in randomized trials using either placebo or active drug controls [
         <a href="#rid22">
          22,23
         </a>
         ]. Published cure rates can vary widely according to the investigators' diagnostic criteria, definition of cure and treatment failure, and length of time post-therapy before the follow-up visit.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Multiday therapy
         </strong>
         – Treatment of symptomatic nonpregnant patients with multiday
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         administered either orally (seven days) or intravaginally (five days) results in a high rate of clinical cure (70 to 80 percent at four weeks of follow-up) [
         <a href="#rid22">
          22,24-27
         </a>
         ]. Most comparative studies using divided-dose oral regimens for one week achieved early cure rates in excess of 90 percent, and cure rates (by Amsel criteria) at four weeks of up to 80 percent [
         <a href="#rid13">
          13,14,22,25,28-30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Longer-course treatment
         </strong>
         – There is little evidence of benefit from prolonging therapy longer than seven days. Although early cure rates are significantly higher when the initial course of
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         therapy is 14 rather than 7 days, long-term cure rates (21 days after completion of therapy) are similar for both treatment regimens [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H614023997">
         <span class="h2">
          Clindamycin
         </span>
         <span class="headingEndMark">
          —
         </span>
         When selected for treatment of BV,
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         is typically given as a vaginal cream for seven nights  (
         <a class="graphic graphic_table graphicRef77648" href="/z/d/graphic/77648.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef131909" href="/z/d/graphic/131909.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. While oral clindamycin is an alternative treatment option, it is less preferred because of potential risk of
         <em>
          Clostridioides
         </em>
         (formerly
         <em>
          Clostridium
         </em>
         )
         <em>
          difficile
         </em>
         -associated diarrhea [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Preferred
         </strong>
         – The preferred regimen is
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         cream 2% given vaginally as 5 grams of cream daily for seven days (5 grams of cream contains 100 mg of clindamycin phosphate) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Alternative regimens
         </strong>
         – Alternative regimens include [
         <a href="#rid1">
          1,33
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          Clindamycin
         </a>
         300 mg twice daily orally for seven days
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <strong>
          or
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          Clindamycin
         </a>
         100 mg vaginal suppositories at bedtime for three days
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Less-preferred regimens
         </strong>
         –
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          Clindamycin
         </a>
         2% is also available as a single-dose bioadhesive cream (commercial name Clindesse) or gel (commercial name Xaciato). Both are given as a single 5 g intravaginal dose of product containing 100 mg of clindamycin phosphate [
         <a href="#rid34">
          34,35
         </a>
         ]. The products can be inserted at any time of day.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Cream
         </strong>
         – While the 21-day BV cure rates of single-dose and multidose
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         cream were similar in one study (64.3 versus 63.2 percent), methodologic limitations prevented definitive conclusions regarding efficacy and therefore we prefer multiday regimens [
         <a href="#rid1">
          1,36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Gel
         </strong>
         –
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          Clindamycin
         </a>
         2% vaginal gel (commercial name Xaciato) is an effective single-day treatment for BV; data comparing the efficacy of single-day gel with multiday regimens are not yet available. In a trial comparing single-dose clindamycin 2% gel with placebo in 307 individuals with BV, 21-day cure rates were 86 versus 21 percent for clinical cure, 53 versus 3 percent for biological cure, and 45 versus 3 percent for therapeutic cure [
         <a href="#rid35">
          35,37
         </a>
         ]. Treatment-emergent adverse events were more common in patients receiving clindamycin gel than placebo (15.3 versus 9.7 percent, respectively); 9.4 percent of the adverse events in the treatment group were related to vulvovaginal candidiasis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Common
         </strong>
         – The most common adverse effects are vulvovaginal candidiasis (topical and oral formulations) and gastrointestinal side effects (oral formulation) [
         <a href="#rid38">
          38,39
         </a>
         ]. Although uncommon, pseudomembranous colitis has been reported with both formulations.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          Clindamycin
         </a>
         <strong>
          resistance
         </strong>
         – Intravaginal clindamycin therapy has been associated with an increased prevalence of clindamycin-resistant anaerobic bacteria in the vagina post-treatment (17 percent of bacterial isolates before versus 53 percent of isolates after therapy) [
         <a href="#rid40">
          40
         </a>
         ]. This effect persisted in most women for at least 90 days after clindamycin treatment. However, given the generally similar cure rates between clindamycin and
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         regimens, the clinical significance of this finding is unclear.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Impact on latex condoms
         </strong>
         <strong>
          or diaphragms
         </strong>
         – Latex condoms or diaphragms should not be used concurrently, or within 72 hours of treatment, with
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         cream. Clindamycin cream may weaken latex.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – The efficacy of oral and vaginal
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         preparations have been demonstrated in a meta-analysis of randomized trials, both comparative and placebo controlled [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2590724241">
         <span class="h2">
          Tinidazole
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          Tinidazole
         </a>
         is a second-generation nitroimidazole that is considered an alternative regimen if
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         and
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         are unavailable or not tolerated [
         <a href="#rid1">
          1
         </a>
         ]. It has a longer half-life than metronidazole (12 to 14 hours versus 7 to 8 hours) and fewer side effects reported in some, but not all, studies [
         <a href="#rid41">
          41,42
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dose
         </strong>
         – If used, we suggest 1 gram orally once daily for five days, as efficacy is slightly higher and side effects are slightly less frequent than with shorter-course therapy (
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          tinidazole
         </a>
         2 grams orally daily for two days) [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – In initial clinical trials with variable designs and treatment indications, 11 percent of patients reported adverse effects with a single 2-gram dose of
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          tinidazole
         </a>
         [
         <a href="#rid44">
          44
         </a>
         ]. The most common were a metallic/bitter taste (3.7 percent), nausea (3.2 percent), and weakness or fatigue (2.1 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Randomized trials have shown that it is at least as effective as
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         , but not superior [
         <a href="#rid43">
          43,45-47
         </a>
         ], and a single-dose regimen appears to be as effective as vaginal
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         cream [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4088631298">
         <span class="h2">
          Secnidazole
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="114899" href="/z/d/drug information/114899.html" rel="external">
          Secnidazole
         </a>
         is a nitroimidazole antibiotic with a longer half-life than
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         (approximately 17 to 19 hours versus 7 to 8 hours) that is considered an alternative regimen for BV [
         <a href="#rid1">
          1,49
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dose
         </strong>
         –
         <a class="drug drug_general" data-topicid="114899" href="/z/d/drug information/114899.html" rel="external">
          Secnidazole
         </a>
         is prescribed as a single 2-gram packet of granules that are taken once orally, typically mixed into a soft food (ie, applesauce, yogurt, or pudding) [
         <a href="#rid50">
          50
         </a>
         ]. The mixture should be consumed within 30 minutes, and the granules should not be crunched or chewed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Compared with placebo, treatment with
         <a class="drug drug_general" data-topicid="114899" href="/z/d/drug information/114899.html" rel="external">
          secnidazole
         </a>
         is more likely to result in vulvovaginal candidiasis (nearly 9.6 percent), headache (3.6 percent), nausea (3.6 percent), diarrhea (2.5 percent), and abdominal pain (2 percent) [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – In a phase 3 trial comparing a single 2-gram dose of oral
         <a class="drug drug_general" data-topicid="114899" href="/z/d/drug information/114899.html" rel="external">
          secnidazole
         </a>
         with placebo, single-dose secnidazole was superior to placebo, with clinical outcome responder rates of 53 versus 19 percent [
         <a href="#rid49">
          49
         </a>
         ]. A single 1-gram oral dose of secnidazole appears to be effective as well [
         <a href="#rid51">
          51,52
         </a>
         ]. Although compliance is enhanced by the convenience of a single-dose regimen, there is no evidence demonstrating that single-dose secnidazole is superior to multidose
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         therapy, which typically is less expensive. While previously available in other countries, secnidazole was approved for the treatment of BV by the US Food and Drug Administration (FDA) in 2017 [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1705669924">
         <span class="h2">
          Dequalinium chloride
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="139621" href="/z/d/drug information/139621.html" rel="external">
          Dequalinium
         </a>
         chloride is a quaternary ammonium compound that functions as a local antiseptic and is available in Canada and Europe (not available in the US) [
         <a href="#rid53">
          53,54
         </a>
         ]. One dequalinium chloride 10 mg tablet is inserted vaginally at bedtime for six consecutive nights [
         <a href="#rid53">
          53
         </a>
         ]. A clinical trial comparing dequalinium treatment (n = 163) with a standard
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         cream (n = 152) reported early clinical cure rates (ie, 3 to 14 days after end of therapy) of 81.5 and 78.4 percent, respectively [
         <a href="#rid55">
          55
         </a>
         ]. The role in primary treatment of BV in diverse populations is unclear [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
         Product use is limited by the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient age
         </strong>
         – Patients should be aged 18 to 55 years of age as data on patients &lt;18 years and &gt;55 years are not yet available [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Menses
         </strong>
         – The product should not be used during menses because local drug concentrations cannot be ensured [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sexual intercourse
         </strong>
         – As data on the impact of vaginal intercourse on drug efficacy are insufficient, patients are advised to refrain from vaginal sexual activity during treatment [
         <a href="#rid53">
          53
         </a>
         ]. Additionally, data are insufficient to assess the drug's impact on condoms, diaphragms, menstrual cups, and related devices. Thus, use of these products is not advised during treatment with
         <a class="drug drug_general" data-topicid="139621" href="/z/d/drug information/139621.html" rel="external">
          dequalinium
         </a>
         chloride.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pregnancy, lactation, and birth
         </strong>
         – Data on drug safety in pregnancy are limited, although reassuring to date, and drug excretion in breast milk is not known [
         <a href="#rid53">
          53
         </a>
         ]. Additionally, patients are advised to avoid use of
         <a class="drug drug_general" data-topicid="139621" href="/z/d/drug information/139621.html" rel="external">
          dequalinium
         </a>
         within 48 hours of intercourse if attempting to conceive and to avoid the drug within 12 hours of vaginal delivery.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Limited data from diverse populations
         </strong>
         – The vast majority of participants in the above trial were White [
         <a href="#rid55">
          55
         </a>
         ]. Larger clinical trials that include diverse patient populations are needed to fully understand the efficacy and optimal use of this medication [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3134200982">
         <span class="h1">
          PROBIOTICS AND OTHER THERAPIES
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Probiotics
         </strong>
         – Probiotics (live microorganisms that confer a health benefit on the host when administered in adequate amounts) have been used alone and as adjunctive therapy to antibiotics for treatment of BV and prevention of relapse. Systemic reviews of clinical trials of probiotics for treatment of BV have not found sufficient evidence for or against efficacy [
         <a href="#rid57">
          57,58
         </a>
         ]. Although some trials have reported very promising results, particularly for treatment with a human-derived
         <em>
          L. crispatus
         </em>
         strain, larger trials that demonstrate treatment efficacy are needed before use of this therapy is considered [
         <a href="#rid59">
          59
         </a>
         ]. In addition, further investigation is needed to determine the optimum route of administration (oral or vaginal), which strains or combination of strains are most effective (eg,
         <em>
          Lactobacillus rhamnosus
         </em>
         GR-1,
         <em>
          Lactobacillus reuteri
         </em>
         RC-14,
         <em>
          Lactobacillus acidophilus
         </em>
         ), the timing of administration relative to antibiotic therapy, and the dose and duration of use [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Less effective
         </strong>
         –
         <strong>
         </strong>
         Cure rates with
         <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">
          ampicillin
         </a>
         and
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         are mediocre. Boric acid has not been shown to be effective in treating isolated or initial cases of BV. While boric acid may play a supportive role in treatment with primary antibiotic therapy, it is not to be used for primary treatment. There is a role for boric acid vaginal suppositories in patients with relapsing or recurrent BV when used in combination with antimicrobial agents. A novel form of boric acid is under investigation [
         <a href="#rid61">
          61
         </a>
         ]. (See
         <a class="local">
          'Persistent or repeat symptoms'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ineffective
         </strong>
         – Triple-sulfa creams,
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          tetracycline
         </a>
         ,
         <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">
          ampicillin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         , lactic acid gel,
         <a class="drug drug_general" data-topicid="9277" href="/z/d/drug information/9277.html" rel="external">
          acetic acid
         </a>
         gel, ascorbic acid,
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">
          chlorhexidine
         </a>
         ,
         <a class="drug drug_general" data-topicid="113931" href="/z/d/drug information/113931.html" rel="external">
          hydrogen peroxide
         </a>
         ,
         <a class="drug drug_general" data-topicid="134822" href="/z/d/drug information/134822.html" rel="external">
          vaginal boric acid
         </a>
         as an isolated therapy, and povidone-iodine vaginal douches are significantly less effective for the treatment of BV than
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         and
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         and should not be used [
         <a href="#rid31">
          31,62-68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with recurrent BV, long-term suppressive oral or topical
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         regimens are not advised because of toxicity (oral) and lack of documented efficacy (topical) [
         <a href="#rid69">
          69
         </a>
         ]. In our experience, long-term clindamycin therapy is frequently associated with vaginal yeast coinfections compared with
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         gel. Clindamycin should not be used in patients with a history
         <em>
          of C. difficile
         </em>
         infection.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3260942304">
         <span class="h1">
          PATIENTS WHO REQUIRE TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         We treat all patients with confirmed BV who are symptomatic or who are undergoing a gynecologic procedure involving the vagina (regardless of symptoms) [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3752054228">
         <span class="h2">
          Symptomatic
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with confirmed BV infection and symptoms are treated because symptoms are significantly bothersome and treatment may reduce the risk of acquiring sexually transmitted infections. (See
         <a class="local">
          'Rationale for treatment'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H964546720">
         <span class="h3">
          Nonpregnant
         </span>
         <span class="headingEndMark">
          —
         </span>
         Symptomatic nonpregnant patients are treated as below. Treatment is extrapolated to patients with a surgical neovagina as data supporting need for an alternate approach are lacking.
         <strong>
         </strong>
        </p>
        <p class="headingAnchor" id="H2387753996">
         <span class="h4">
          Preferred treatments
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         and
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         , as oral or vaginal formulations, are preferred therapies for BV and have similar treatment efficacy  (
         <a class="graphic graphic_algorithm graphicRef131909" href="/z/d/graphic/131909.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid1">
          1,2
         </a>
         ]. The choice of medication is based on availability, patient preferences, side effects, cost, and history of response or adverse reactions [
         <a href="#rid27">
          27
         </a>
         ]. Treatment does not vary with HIV infection. This treatment approach is extrapolated to individuals who have undergone vaginoplasty. (See
         <a class="medical medical_review" href="/z/d/html/114517.html" rel="external">
          "Gender-affirming surgery: Male to female", section on 'Genital (bottom) surgery (vaginoplasty)'
         </a>
         .)
        </p>
        <p>
         The following treatment recommendations are consistent with those of the World Health Organization (WHO) and the United States Centers for Disease Control and Prevention (CDC)  (
         <a class="graphic graphic_algorithm graphicRef131909" href="/z/d/graphic/131909.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid1">
          1,2
         </a>
         ]. Guidelines from other organizations are available elsewhere [
         <a href="#rid70">
          70,71
         </a>
         ]. Oral
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         is commonly used because oral treatment is often preferred by patients rather than intravaginal therapy and metronidazole is less commonly associated with
         <em>
          Clostridioides
         </em>
         <em>
          difficile
         </em>
         infection compared with oral
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          Metronidazole
         </a>
         500 mg orally twice daily for seven days [
         <a href="#rid1">
          1,2
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <strong>
          or
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          Metronidazole
         </a>
         gel 0.75% one full applicator (5 g) intravaginally, once daily for five days [
         <a href="#rid1">
          1
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <strong>
          or
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          Clindamycin
         </a>
         cream 2% one full applicator (5 g) intravaginally at bedtime for seven days [
         <a href="#rid1">
          1
         </a>
         ]. We prefer vaginal clindamycin over
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         gel if the patient has only been treated with metronidazole to date [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2849055208">
         <span class="h4">
          Alternative therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         If the preferred therapies are not available or if the patient prefers a shorter duration of treatment,
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         intravaginal ovules, oral
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          tinidazole
         </a>
         , and oral
         <a class="drug drug_general" data-topicid="114899" href="/z/d/drug information/114899.html" rel="external">
          secnidazole
         </a>
         are reasonable treatment alternatives. Efficacy appears similar to
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         and clindamycin although supporting data are limited. For tinidazole and secnidazole, the benefits of a shorter treatment duration may be offset by higher cost and lack of longer-term outcomes data, which is the rationale for making these drugs alternates [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          Clindamycin
         </a>
         300 mg orally twice daily for seven days [
         <a href="#rid1">
          1,2
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <strong>
          or
         </strong>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          Clindamycin
         </a>
         ovules 100 mg intravaginally at bedtime for three days [
         <a href="#rid1">
          1
         </a>
         ]. Use of this product may weaken latex or rubber contraceptives such as condoms or diaphragms. Patients should wait 72 hours after use of clindamycin ovules before using latex or rubber condoms or diaphragms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <strong>
          or
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="114899" href="/z/d/drug information/114899.html" rel="external">
          Secnidazole
         </a>
         2 g oral granules in a single dose (sprinkled onto unsweetened applesauce, yogurt, or pudding before ingestion) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         <strong>
          or
         </strong>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          Tinidazole
         </a>
         2 g orally once daily for two days [
         <a href="#rid1">
          1
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <strong>
          or
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          Tinidazole
         </a>
         1 g orally once daily for five days [
         <a href="#rid1">
          1
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2978026949">
         <span class="h3">
          Pregnant or lactating persons
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pregnancy
         </strong>
         – Pregnant persons with symptomatic BV are treated to relieve bothersome symptoms. In a meta-analysis of 10 trials comparing antibiotic therapy with placebo for individuals with confirmed BV or intermediate vaginal microbiota while pregnant, antibiotic therapy effectively reduced BV during pregnancy (average risk ratio 0.42, 95% CI 0.31-0.56, 10 trials, 4403 women) [
         <a href="#rid72">
          72
         </a>
         ]. While oral and vaginal regimens are available, oral
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         is commonly used as some data indicate greater efficacy of oral metronidazole against upper tract infection compared with other options [
         <a href="#rid73">
          73-75
         </a>
         ]. However, not all guidelines agree [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Routine screening of asymptomatic pregnant persons for BV has not been shown to reduce the risk of preterm birth [
         <a href="#rid76">
          76,77
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/140781.html" rel="external">
          "Spontaneous preterm birth: Overview of interventions for risk reduction", section on 'Routinely screening for cervicovaginal and sexually transmitted infections'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Oral treatment regimens
         </strong>
         <strong>
          (preferred)
         </strong>
         – Oral treatment is effective and has not been associated with adverse fetal or obstetric effects [
         <a href="#rid72">
          72,78-82
         </a>
         ]. Therapeutic options include:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          Metronidazole
         </a>
         500 mg orally twice daily for seven days [
         <a href="#rid1">
          1
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <strong>
          or
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          Metronidazole
         </a>
         250 mg orally three times daily for seven days [
         <a href="#rid1">
          1,2,74,75
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <strong>
          or
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          Clindamycin
         </a>
         300 mg orally twice daily for seven days [
         <a href="#rid1">
          1,2,83
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Alternative topical therapy
         </strong>
         – The author and other experts prefer oral therapy in pregnant patients because some data indicate oral treatment is more effective against potential upper genital tract infection [
         <a href="#rid73">
          73-75
         </a>
         ]. However, as topical therapy is not inferior to oral therapy in effecting cure or preventing adverse pregnancy outcomes such as preterm birth, the World Health Organization and US Centers for Disease Control and Prevention (CDC) recommend either oral or topical therapy for treatment of symptomatic pregnant individuals [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The regimens are the same as for nonpregnant patients and include [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          Metronidazole
         </a>
         0.75% gel one full applicator (5 g) intravaginally, once daily for five days (5 grams of gel contains 37.5 mg of metronidazole) [
         <a href="#rid1">
          1,2,84
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <strong>
          or
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          Clindamycin
         </a>
         cream 2% one full applicator (5 g) intravaginally at bedtime for seven nights [
         <a href="#rid1">
          1,85
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Drug safety in pregnancy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          Metronidazole
         </a>
         – Some clinicians avoid use of metronidazole in the first trimester because it crosses the placenta, and thus has a potential for teratogenicity. However, meta-analyses of observational data in pregnant persons have not found any relationship between metronidazole exposure during the first trimester of pregnancy and congenital anomalies [
         <a href="#rid86">
          86-88
         </a>
         ]. The CDC no longer discourages the use of metronidazole in the first trimester [
         <a href="#rid1">
          1
         </a>
         ]; the World Health Organization continues to advise caution with first trimester use [
         <a href="#rid2">
          2
         </a>
         ]. An additional concern is that the drug is mutagenic in bacteria and carcinogenic in mice, but there is no evidence of harm in humans.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Drugs to avoid
         </strong>
         – Limited data are available to inform use of
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          tinidazole
         </a>
         or
         <a class="drug drug_general" data-topicid="114899" href="/z/d/drug information/114899.html" rel="external">
          secnidazole
         </a>
         in pregnant persons. However, as animal data suggests tinidazole is associated with risk, use of this drug for pregnant persons is not advised [
         <a href="#rid1">
          1,89
         </a>
         ]. As the available data on secnidazole is inadequate to determine safety during pregnancy, we and others also avoid using it for pregnant patients [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lactating individuals –
         </strong>
         Lactating individuals with confirmed BV and symptoms are offered treatment while asymptomatic individuals are not. While the treatment options as the same as during pregnancy, some preference is given to
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         as
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         has been associated with infant gastrointestinal symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additional discussions of drug safety during lactation are available
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK501922%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4trystKLNkAhaR%2FcduMJFFebszM73aaFBm717nqYa%2FpVDsg%3D%3D&amp;TOPIC_ID=113103" target="_blank">
          online
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          Metronidazole
         </a>
         <strong>
          (preferred)
         </strong>
         – Our preferred treatment for lactating individuals is metronidazole. Although vaginal metronidazole has not been extensively studied during breastfeeding, plasma levels are less than 2 percent of those after a 500 mg oral dose, so vaginal metronidazole is unlikely to be a safety concern in lactating individuals [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          Metronidazole
         </a>
         500 mg orally twice daily for seven days [
         <a href="#rid1">
          1,2
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <strong>
          or
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          Metronidazole
         </a>
         gel 0.75% one full applicator (5 g) intravaginally, once daily for five days [
         <a href="#rid1">
          1
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Compared with
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         treatment of infection in neonates, breastfed infants receive lower doses of metronidazole through breastmilk secretion [
         <a href="#rid1">
          1
         </a>
         ]. Available human data do not support an association between metronidazole use and cancer although an association with carcinogenesis in rodents has been demonstrated [
         <a href="#rid90">
          90
         </a>
         ]. Maternal metronidazole use does not appear to be associated with increased adverse events compared with use of other antimicrobials, although a cohort study found a nonsignificant trend toward more loose stools and more candidal colonization in metronidazole-exposed infants. Since the relative infant dose of metronidazole is high (29 percent) with use of the maternal 2-gram single dose, a cautious approach for mothers receiving this dose is to express and discard their milk for 12 to 24 hours. This recommendation has not been extended to other metronidazole regimens [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          Clindamycin
         </a>
         – While oral clindamycin is a reasonable therapeutic choice, we prefer oral
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         because clindamycin has the potential to cause adverse effects on the breastfed infant's gastrointestinal microbiota. Infants of patients treated with oral clindamycin should be monitored for diarrhea, candidiasis (thrush, diaper rash) or, rarely, blood in the stool indicating possible antibiotic-associated colitis [
         <a href="#rid90">
          90
         </a>
         ]. Infant side effects are less likely with vaginal clindamycin than oral use since only approximately 30 percent of a vaginal dose is absorbed.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Alternative drugs
         </strong>
         – For lactating individuals who are administered
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          tinidazole
         </a>
         or
         <a class="drug drug_general" data-topicid="114899" href="/z/d/drug information/114899.html" rel="external">
          secnidazole
         </a>
         , interruption of breastfeeding is recommended during treatment and for three days after the last dose based on animal data (tinidazole only) [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H602840462">
         <span class="h2">
          Individuals undergoing gynecologic procedures
         </span>
         <span class="headingEndMark">
          —
         </span>
         For individuals with confirmed BV (with or without symptoms), we suggest antibiotic treatment prior to transvaginal procedures or surgery (eg, pregnancy termination, dilation and curettage, hysterectomy, etc) to reduce the risk of postprocedure infection (cuff infection after hysterectomy, endometritis after termination) [
         <a href="#rid91">
          91-93
         </a>
         ]. Reported reductions in postoperative infectious complications range from 10 to 75 percent [
         <a href="#rid94">
          94-98
         </a>
         ]. There is insufficient evidence to make a conclusion regarding screening for BV prior to intrauterine device insertion [
         <a href="#rid99">
          99
         </a>
         ]. The medication treatment options are the same as for symptomatic nonpregnant patients.
        </p>
        <p class="headingAnchor" id="H3977321671">
         <span class="h1">
          TREATMENT NOT INDICATED
         </span>
         <span class="headingEndMark">
          —
         </span>
         Unless a patient with documented BV infection is undergoing gynecologic surgery involving the vagina, we do not routinely treat individuals with asymptomatic BV. BV is self-limiting in approximately one-third of nonpregnant persons and one-half of pregnant persons [
         <a href="#rid3">
          3-6
         </a>
         ]. In addition, sex partners (female or male) are not treated unless symptoms develop.
        </p>
        <p class="headingAnchor" id="H418460057">
         <span class="h2">
          Asymptomatic nonpregnant
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest observation, and not antibiotic treatment, for asymptomatic nonpregnant individuals [
         <a href="#rid1">
          1,9
         </a>
         ]. Treatment of asymptomatic BV is typically avoided since patients often spontaneously improve over a period of several months and any antibacterial therapy can be followed by symptomatic vaginal yeast infection. Although some experts recommend treatment of asymptomatic BV because affected individuals are more susceptible to acquiring other sexually transmitted infections (STIs, including HIV and herpes simplex virus), available evidence is insufficient to clearly support or exclude a benefit of treatment [
         <a href="#rid93">
          93,100-103
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evidence
         </strong>
         – This practice is supported by a double-blind, placebo-controlled trial of 54 women with asymptomatic BV who were randomly assigned to receive intravaginal
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         or placebo gel [
         <a href="#rid5">
          5
         </a>
         ]. There was no difference in the proportion of women in either group who noticed improvement in vaginal odor or discharge. In addition, 6 of 28 women receiving metronidazole developed symptomatic vaginal candidiasis compared with no women taking placebo.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Exception
         </strong>
         – Asymptomatic individuals with confirmed BV who are planning gynecologic procedures or surgery that involves the vagina are treated. Preoperative treatment of asymptomatic BV has been associated with reduced risk of postoperative infection. (See
         <a class="local">
          'Individuals undergoing gynecologic procedures'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H443124895">
         <span class="h2">
          Asymptomatic pregnant persons
         </span>
         <span class="headingEndMark">
          —
         </span>
         Asymptomatic pregnant individuals with previous preterm births may benefit from treatment, but screening and treatment of these individuals are controversial as the available data do not show a consistent benefit to this approach [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Our approach
         </strong>
         – Based upon the data below, we and others, including the American College of Obstetricians and Gynecologists, United States Preventive Services Task Force, CDC, and Society of Obstetricians and Gynaecologists of Canada, suggest
         <strong>
          not
         </strong>
         routinely screening and treating all pregnant individuals with asymptomatic BV to prevent preterm birth and its consequences [
         <a href="#rid1">
          1,104-107
         </a>
         ]. It is not possible to define specific features characterizing a subgroup of individuals who might respond favorably to a screening and treatment protocol. Defining these features is an active area of investigation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, as illustrated below, there may be benefits to early screening and treatment of asymptomatic pregnant individuals who have a history of a previous preterm delivery, but there are insufficient data to recommend this as a routine practice [
         <a href="#rid79">
          79,108-111
         </a>
         ]. Further definition of high-risk subgroups is under investigation. As an example, individuals with polymorphisms of genes regulating cytokine production (eg, tumor necrosis factor variants) have a greater proinflammatory immune response to infectious stimuli, such as BV [
         <a href="#rid112">
          112
         </a>
         ]. Enhanced induction of cytokines in these individuals could then lead to preterm labor or rupture of membranes. Other aspects of host response (eg, low levels of immunoglobulin A [IgA] to
         <em>
          Gardnerella vaginalis
         </em>
         ) or the specific types of BV-associated bacteria involved (eg, bacteria that produce high levels of sialidase or protease) may also play a role in placing some individuals with BV at high risk of preterm birth. Additional information is available in related content:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6761.html" rel="external">
          "Spontaneous preterm birth: Overview of risk factors and prognosis", section on 'Genetic variants'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk for adverse pregnancy outcomes, including preterm birth
         </strong>
         – As many as one-third of pregnant individuals in the United States have BV [
         <a href="#rid113">
          113
         </a>
         ]. Of concern, a 2007 meta-analysis reported a statistically significant increased risk of preterm birth in these women; the pooled odds ratio (OR) for prematurity was 2.16 (95% CI 1.56-3.00) [
         <a href="#rid114">
          114
         </a>
         ]. The increased risk of preterm birth attributable to BV appears to be linked to preterm labor due to chorioamnionitis [
         <a href="#rid115">
          115,116
         </a>
         ]. Other complications of BV include postpartum endometritis (OR 2.53, 95% CI 1.25-5.08) and an increased risk of late miscarriage (OR 6.32, 95% CI 3.65-10.90) [
         <a href="#rid114">
          114
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Conflicting data for screening and treatment
         </strong>
         – Despite the association between BV and adverse outcome, screening and treatment of asymptomatic BV during pregnancy are controversial and vary in part based on the individual's baseline risk for preterm delivery [
         <a href="#rid107">
          107
         </a>
         ]. Meta-analyses of randomized trials performed in general obstetric populations have generally found that treatment of asymptomatic infection does not reduce the incidence of preterm labor or delivery in the overall obstetric population [
         <a href="#rid72">
          72,85,104
         </a>
         ], but some subgroups of women, such as those at high risk for preterm birth, may benefit. The available evidence is discordant due to differences in selection of trials and differences between the included trials. Examples include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a 2015 Cochrane meta-analysis of eight trials comparing the use of prophylactic antibiotics in the second or third trimester of pregnancy in women at risk for preterm delivery, antibiotic treatment reduced preterm delivery in the subgroup of women with a prior preterm delivery and current BV compared with no treatment (risk ratio 0.64, 95% CI 0.47-0.88, one trial, 258 women) [
         <a href="#rid117">
          117
         </a>
         ]. Antibiotic prophylaxis did not reduce preterm delivery in women with a prior history of preterm birth who did not have BV.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a 2013 Cochrane meta-analysis including 21 trials involving 7847 pregnant women with BV (symptomatic or asymptomatic) detected through screening, antibiotic therapy was highly effective in eradicating infection but did not significantly reduce the odds of preterm birth at less than 37 weeks (OR 0.88, 95% CI 0.71-1.09) or the risk of preterm premature rupture of membranes (OR 0.74, 95% CI 0.30-1.84) [
         <a href="#rid72">
          72
         </a>
         ]. Treatment initiated before 20 weeks of gestation also did not reduce the risk of preterm birth before 37 weeks (OR 0.85, 95% CI 0.62-1.17).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         When the Cochrane reviewers separately analyzed the subgroup of women with a history of one or more prior preterm births (ie, women at high risk for preterm birth), the detection and treatment of BV still did not significantly reduce the risk of preterm birth (OR 0.78, 95% CI 0.42-1.48, three trials, 421 women).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a 2011 meta-analysis of five randomized trials of asymptomatic women with BV at &lt;22 weeks of gestation treated with
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         or placebo/no treatment, clindamycin therapy was associated with a reduction in preterm birth &lt;37 weeks (3.7 percent [44 out of 1183] versus 6.2 percent [72 out of 1163]; fixed effects relative risk [RR] 0.60, 95% CI 0.42-0.86, random effects 0.64, 95% CI 0.39-1.05) and late miscarriage (0.3 percent [2 out of 639] versus 1.9 percent [12 out of 631]; RR 0.20, 95% CI 0.05-0.76) [
         <a href="#rid85">
          85
         </a>
         ]. Subgroup analysis revealed that oral, not vaginal, clindamycin therapy was associated with a significant reduction in preterm birth (oral therapy RR 0.39, 95% CI 0.20-0.76; vaginal RR 0.73, 95% CI 0.47-1.14). The analysis included a mixed population of women at both low and high risk of preterm birth.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Therapeutic options if treatment is elected
         </strong>
         – When the decision is made to treat asymptomatic pregnant individuals who have confirmed BV because of prior history, the optimal choice of antibiotic, timing of therapy, duration of use, and harms of therapy are debated. Based on the data presented below, we use oral therapy when treatment is indicated and consider both
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         and
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         acceptable choices.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          Metronidazole
         </a>
         – The first trials demonstrated a reduction in preterm birth in high-risk women treated with oral metronidazole or oral metronidazole and
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         (
         <a class="graphic graphic_table graphicRef60950" href="/z/d/graphic/60950.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid73">
          73-75
         </a>
         ]. However, in two studies, metronidazole use in pregnancy appeared to increase the risk of preterm birth [
         <a href="#rid118">
          118,119
         </a>
         ]. This association requires further investigation and confirmation before avoiding metronidazole for treatment of BV in pregnancy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          Clindamycin
         </a>
         – Trials suggest that oral clindamycin given early in pregnancy is an effective therapy [
         <a href="#rid85">
          85
         </a>
         ]. Topical clindamycin given in the second half of pregnancy is less effective and even associated with an increase in low birth weight and neonatal infection [
         <a href="#rid120">
          120
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H523364980">
         <span class="h2">
          Asymptomatic sex partners
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although sexual activity is a risk factor for transmission, the data do not support treatment of asymptomatic sex partners of individuals with confirmed BV. (See
         <a class="local">
          'Nonpregnant'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H676542293">
         <span class="h3">
          Males
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no strong evidence that treatment of sex partners who have a penis impacts the treatment success or risk of recurrence for the patient with confirmed BV [
         <a href="#rid1">
          1,121-123
         </a>
         ]. Until population-specific data are available, this thinking is extrapolated to patients who have undergone surgical phalloplasty as well. (See
         <a class="medical medical_review" href="/z/d/html/114516.html" rel="external">
          "Gender-affirming surgery: Female to male", section on 'Phalloplasty with genital reconstruction'
         </a>
         .)
        </p>
        <p>
         Relevant studies include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a 2016 meta-analysis of seven trials assessing efficacy of BV treatment versus placebo in women and their male sex partners, antibiotic treatment of the male sex partners did not increase the rate of clinical or symptomatic improvement for the index patients nor did it reduce recurrence rates during a four-week study period [
         <a href="#rid121">
          121
         </a>
         ]. The men in the treatment group reported more adverse events compared with men in the placebo group but most events were minor.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a trial of 214 individuals with recurrent BV, seven-day
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         treatment of male partners, compared with placebo treatment, did not reduce BV recurrence in intention-to-treat analysis [
         <a href="#rid123">
          123
         </a>
         ]. Although not statistically significant, BV recurrence was less likely in individuals whose male partners were adherent to the study medication.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1073707378">
         <span class="h3">
          Females
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals with a vagina who are sex partners of those with confirmed BV should be educated about the signs and symptoms of BV given the high risk of concordant infection (25 to 50 percent) [
         <a href="#rid124">
          124-126
         </a>
         ]. If symptoms subsequently develop in a sex partner and BV is confirmed, treatment is indicated for relief of symptoms. It has been hypothesized that behavioral interventions that reduce transfer of vaginal fluid between sex partners may be helpful (eg, cleaning sex toys between use, use of gloves during digital-vaginal sex); however, a small randomized trial evaluating this approach reported no reduction in BV persistence [
         <a href="#rid127">
          127
         </a>
         ]. Further study is needed. (See
         <a class="medical medical_review" href="/z/d/html/5426.html" rel="external">
          "Sexual and gender minority women (lesbian, gay, bisexual, transgender, plus): Medical and reproductive care", section on 'Sexually transmitted infection'
         </a>
         .)
        </p>
        <p>
         This treatment approach is extrapolated to individuals who have undergone surgical vaginoplasty. (See
         <a class="medical medical_review" href="/z/d/html/114517.html" rel="external">
          "Gender-affirming surgery: Male to female", section on 'Genital (bottom) surgery (vaginoplasty)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H414141470">
         <span class="h1">
          TREATMENT RESPONSE AND PATIENT FOLLOW-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment response is anticipated in 70 to 80 percent of patients; response rates vary by choice of drug, duration of treatment, and patient population (eg, initial or recurrent BV). Efficacy of treatment by drug is discussed above. (See
         <a class="local">
          'Drug description and selection'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptoms resolve
         </strong>
         – Routine follow-up visits are not required if symptoms resolve [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptoms persist or return
         </strong>
         – Patients whose symptoms persist despite adequate treatment or whose symptoms return quickly (ie, within a few weeks) are re-evaluated for BV and other causes of abnormal vaginal discharge are excluded. If BV is confirmed as the likely cause of symptoms, the patient is treated for repeat infection. Identification of prognostic markers that reliably predict outcome, and thus provide opportunities to modify therapy, are an area of active research [
         <a href="#rid128">
          128,129
         </a>
         ]. (See
         <a class="local">
          'Persistent or repeat symptoms'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2310740770">
         <span class="h1">
          PERSISTENT OR REPEAT SYMPTOMS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients may have symptoms that persist despite adequate treatment or may experience rapid (ie, within a few weeks) return of symptoms. We educate patients that periodic recurrences of BV are common but do not necessarily represent recurrent BV. Recurrent BV is defined as three or more confirmed episodes within one year. (See
         <a class="medical medical_review" href="/z/d/html/131928.html" rel="external">
          "Bacterial vaginosis: Recurrent infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2627570357">
         <span class="h2">
          Definition and prevalence
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          BV relapse versus reinfection
         </strong>
         – Potential explanations for confirmed repeat BV infection include relapse or reinfection. Relapse, the more likely mechanism, can reflect inadequate initial treatment (eg, incorrect use of medication or early cessation of therapy), failure to eradicate the offending organisms, or inability reestablish the normal protective vaginal microbiota dominated by lactobacillus. Infections involving biofilms can be more difficult to eradicate [
         <a href="#rid130">
          130
         </a>
         ]. These mechanisms may explain the persistence of pathogenic bacteria, as documented by 16S rRNA sequencing and polymerase chain reaction (PCR) testing, in patients with documented infection who are treated with seven days of oral
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         therapy [
         <a href="#rid131">
          131
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The only interventions proven to reduce development or recurrence of BV are chronic suppressive therapy and circumcision of male partners [
         <a href="#rid132">
          132,133
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/131928.html" rel="external">
          "Bacterial vaginosis: Recurrent infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevalence
         </strong>
         – Approximately 30 percent of patients with initial responses to therapy have a recurrence of symptoms within three months [
         <a href="#rid28">
          28
         </a>
         ], and more than 50 percent experience a recurrence within 12 months [
         <a href="#rid134">
          134
         </a>
         ]. The explanation for this high rate of repeat infection is unclear.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Recurrent BV
         </strong>
         – Patients with three or more documented BV infections in one year are diagnosed with recurrent BV. Management of patients with recurrent BV is discussed below. (See
         <a class="medical medical_review" href="/z/d/html/131928.html" rel="external">
          "Bacterial vaginosis: Recurrent infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H188502762">
         <span class="h2">
          Confirm BV
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who develop recurrent BV symptoms, including abnormal vaginal discharge and odor, are re-evaluated to confirm BV and exclude other etiologies of vaginal discharge. (See
         <a class="medical medical_review" href="/z/d/html/5477.html" rel="external">
          "Vaginitis in adults: Initial evaluation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H947819197">
         <span class="h2">
          Retreatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Limited data are available regarding the optimal treatment strategy for patients with rapid return of BV [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Induction therapy –
         </strong>
         We retreat patients with symptomatic confirmed repeat BV with a seven-day course of oral or vaginal
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         or
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If one drug class or route has not been previously prescribed, we start with that medication.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the patient has tried multiple drugs in the past, then we repeat whichever drug seemed most helpful or was better tolerated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Suppressive therapy
         </strong>
         –
         <strong>
         </strong>
         Patients with a propensity for repeated BV infections, but who do not meet the criteria for recurrent BV, may benefit from extended or adjunct therapy after initial antibiotic treatment. We take this approach for patients who experience repeat infections less than six months from initial treatment. We start with extended treatment with
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         gel because it is readily available. For patients in whom extended metronidazole gel has not been helpful or effective, we then add adjunct
         <a class="drug drug_general" data-topicid="134822" href="/z/d/drug information/134822.html" rel="external">
          vaginal boric acid
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Management of patients with recurrent BV, defined as three or more documented infections in one year, is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/131928.html" rel="external">
          "Bacterial vaginosis: Recurrent infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          Metronidazole
         </a>
         <strong>
          gel suppressive therapy
         </strong>
         – After completion of induction antibiotic therapy, we treat with metronidazole gel 0.75% one full applicator (5 g) intravaginally twice-weekly for four to six months [
         <a href="#rid1">
          1
         </a>
         ]. We re-evaluate patients yearly and use a symptom-driven approach to determine further treatment [
         <a href="#rid56">
          56
         </a>
         ]. We counsel patients to avoid intravaginal metronidazole or intercourse starting one day prior to evaluation. We do not repeat molecular tests (ie, nucleic acid amplification tests [NAATs]) as they have not been validated for test of cure.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Asymptomatic
         </strong>
         – Asymptomatic patients are continued on
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         gel twice weekly. The rationale is that we prefer to continue successful suppressive therapy rather than wait for repeat infection and need for more intensive treatment [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Symptomatic
         </strong>
         – Symptomatic patients are retreated for repeat infection. Initial antibiotic therapy consists of the drug that has not yet been used or that resulted in the best past response. For patients who developed BV symptoms while on suppressive therapy with
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         gel, we typically add
         <a class="drug drug_general" data-topicid="134822" href="/z/d/drug information/134822.html" rel="external">
          vaginal boric acid
         </a>
         in combination with antibiotic treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Combination therapy with adjunct
         </strong>
         <a class="drug drug_general" data-topicid="134822" href="/z/d/drug information/134822.html" rel="external">
          vaginal boric acid
         </a>
         –
         <strong>
          Vaginal
         </strong>
         boric acid suppositories can be used simultaneously with induction antibiotic treatment [
         <a href="#rid1">
          1,135
         </a>
         ]. For this approach,
         <strong>
          vaginal
         </strong>
         boric acid 600 mg once daily at bedtime is begun simultaneously with the antibiotic and continued for a total of 20 to 30 days [
         <a href="#rid1">
          1
         </a>
         ]. Patients are seen for follow-up a day or two after their last vaginal boric acid dose; if they are in remission, we immediately begin
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         gel twice weekly for four to six months as suppressive therapy. Therapy is then discontinued once treatment has been completed.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <strong>
          Boric acid can cause death if consumed orally
         </strong>
         ; patients should be told to store boric acid in a secure place that is inaccessible to children. Boric acid should not be used by individuals who are pregnant or attempting conception. Sex partners of patients treated with
         <a class="drug drug_general" data-topicid="134822" href="/z/d/drug information/134822.html" rel="external">
          vaginal boric acid
         </a>
         have reported skin irritation after exposure [
         <a href="#rid136">
          136
         </a>
         ]. The magnitude and duration of risk from the time of boric acid use is not known.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with
         </strong>
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         <strong>
          allergy
         </strong>
         –Although supporting data are lacking, those with a metronidazole allergy can either undergo metronidazole desensitization (our preference) or be treated with topical
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         gel. In our experience, clindamycin therapy is frequently associated with vaginal yeast coinfections compared with metronidazole gel. Clindamycin should not be used in patients with a history of
         <em>
          C. difficile
         </em>
         infection.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3502677056">
         <span class="h2">
          Clinical expectations
         </span>
         <span class="headingEndMark">
          —
         </span>
         We educate patients that repeat infection is common and is not necessarily diagnostic of recurrent BV. Studies have reported repeat BV episodes in up to 30 percent of patients at three months from treatment and in nearly 60 percent by 12 months [
         <a href="#rid134">
          134,137,138
         </a>
         ]. Patients who responded well to initial treatment are anticipated to respond well again. As recurrent BV requires more intensive treatment and the diagnosis can be stigmatizing, it is important to limit this diagnosis to individuals with three or more confirmed episodes in one year. (See
         <a class="medical medical_review" href="/z/d/html/131928.html" rel="external">
          "Bacterial vaginosis: Recurrent infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2429609692">
         <span class="h2">
          Ineffective therapies
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vaginal acidifying agents
         </strong>
         – Vaginal acidifying agents, although popular and widely used, have no role in the treatment of acute or chronic BV, as they have never been shown to enhance cure rates. A newly available vaginal gel containing lactic acid, citric acid, and potassium bitartrate (commercial name Phexxi) has been shown to be an effective on-demand contraception; however, its role in maintaining normal vaginal pH as management for BV has not been studied. (See
         <a class="medical medical_review" href="/z/d/html/3265.html" rel="external">
          "Pericoital (on demand) contraception: Diaphragm, cervical cap, spermicides, and sponge", section on 'Vaginal spermicide and pH regulator gel'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Douching should be avoided.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Probiotics
         </strong>
         – In a randomized trial, probiotics were not more effective than placebo for prevention of relapse [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2948253384">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109421.html" rel="external">
          "Society guideline links: Bacterial vaginosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1031530406">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15592.html" rel="external">
          "Patient education: Bacterial vaginosis (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/8424.html" rel="external">
          "Patient education: Bacterial vaginosis (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3000220611">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Who to treat and rationale
         </strong>
         – We treat all symptomatic persons with confirmed bacterial vaginosis (BV) to reduce symptoms (typically vaginal discharge and odor). We also treat patients with confirmed BV who are undergoing gynecologic procedures that involve the vagina, regardless of symptoms, to reduce the risk of postoperative complications. We typically do not treat other asymptomatic individuals because BV infection is self-limited and any antibacterial therapy can be followed by symptomatic vaginal yeast infection. (See
         <a class="local">
          'Rationale for treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptomatic patients
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Nonpregnant
         </strong>
         – For nonpregnant persons with confirmed symptomatic BV, we suggest multiday treatment with
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         or
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         rather than treatment with other antibiotics  (
         <a class="graphic graphic_algorithm graphicRef131909" href="/z/d/graphic/131909.html" rel="external">
          algorithm 1
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). As efficacy is similar for oral or vaginal regimens of both metronidazole or clindamycin, choice of treatment route is driven by patient preference around treatment route, drug availability, and cost. Treatment of patients with a neovagina and/or HIV infection is the same. (See
         <a class="local">
          'Preferred treatments'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Preferred treatment regimens include
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          Metronidazole
         </a>
         500 mg twice daily orally for seven days.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <strong>
          or
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          Metronidazole
         </a>
         gel 0.75% (5 grams containing 37.5 mg metronidazole) once daily vaginally for five days.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <strong>
          or
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          Clindamycin
         </a>
         2% vaginal cream once daily at bedtime for seven days. During therapy with clindamycin cream, latex condoms should not be used.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Alternate regimens
         </strong>
         – Oral
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          tinidazole
         </a>
         and
         <a class="drug drug_general" data-topicid="114899" href="/z/d/drug information/114899.html" rel="external">
          secnidazole
         </a>
         have demonstrated efficacy similar to oral
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         and convenient dosing. However, as they also tend to be of higher cost and lesser availability, they are considered alternatives to the treatments above. (See
         <a class="local">
          'Alternative therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pregnant or lactating
         </strong>
         – For pregnant or lactating patients with symptomatic BV, we suggest oral
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         or
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         rather than intravaginal formulations  (
         <a class="graphic graphic_algorithm graphicRef131909" href="/z/d/graphic/131909.html" rel="external">
          algorithm 1
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The author and other experts prefer oral therapy in pregnant persons because some data indicate oral treatment is more effective against potential upper genital tract infection. Treatment of lactating individuals is the same as for pregnant persons with some preference is given to metronidazole as clindamycin has been associated with gastrointestinal symptoms in infants. (See
         <a class="local">
          'Pregnant or lactating persons'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          Metronidazole
         </a>
         500 mg twice daily orally for seven days (preferred in lactating individuals)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <strong>
          or
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          Clindamycin
         </a>
         300 mg orally twice daily for seven days
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Planned gynecologic surgery
         </strong>
         – For individuals who are undergoing gynecologic procedures involving the vagina, we suggest testing and treatment of confirmed BV rather than observation, even in the absence of symptoms (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Preoperative treatment decreases the frequency of postoperative infectious complications. (See
         <a class="local">
          'Individuals undergoing gynecologic procedures'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Asymptomatic individuals
         </strong>
         – For asymptomatic individuals, we suggest observation rather than antibiotic treatment (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ), unless they are undergoing gynecologic surgery. Treatment is typically avoided since patients often spontaneously improve over a period of several months and any antibacterial therapy is often followed by symptomatic vaginal yeast infection. One exception is patients undergoing gynecologic surgery who are treated regardless of symptoms. (See
         <a class="local">
          'Asymptomatic nonpregnant'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Specific sub-populations for consideration include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Asymptomatic pregnant persons
         </strong>
         – For asymptomatic pregnant individuals, we suggest not screening or treating for BV (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). There is no consistent evidence that screening and treatment of asymptomatic infection during pregnancy reduces the risk of preterm birth. (See
         <a class="local">
          'Pregnant or lactating persons'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Asymptomatic sex partners
         </strong>
         – For sex partners of individuals with confirmed BV, we recommend not treating empirically with antibiotics (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Antibiotic treatment of sex partners has not been associated with increased rates of clinical or symptomatic improvement for the index patient nor reduction of recurrence rates and antibiotic therapy has been associated with side effects. Sex partners of a patient with confirmed BV who themselves have a vagina or surgical neovagina should be educated about the signs and symptoms of BV given the high risk of concordant infection (25 to 50 percent). (See
         <a class="local">
          'Asymptomatic sex partners'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptom recurrence
         </strong>
         –
         <strong>
         </strong>
         Approximately 30 percent of patients with an initial response to therapy have a recurrence of symptoms within three months and nearly 60 percent experience a recurrence within 12 months. We treat symptomatic recurrence using a different antibiotic than that used for the initial episode when possible. (See
         <a class="local">
          'Persistent or repeat symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Individuals with three or more documented BV episodes in one year are defined as having recurrent BV. (See
         <a class="medical medical_review" href="/z/d/html/131928.html" rel="external">
          "Bacterial vaginosis: Recurrent infection"
         </a>
         .)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021; 70:1.
          </a>
         </li>
         <li class="breakAll">
          Guidelines for the management of symptomatic sexually transmitted infections. World Health Organization. June 2021. https://www.who.int/publications/i/item/9789240024168 (Accessed on July 06, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klebanoff MA, Hauth JC, MacPherson CA, et al. Time course of the regression of asymptomatic bacterial vaginosis in pregnancy with and without treatment. Am J Obstet Gynecol 2004; 190:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hay PE, Morgan DJ, Ison CA, et al. A longitudinal study of bacterial vaginosis during pregnancy. Br J Obstet Gynaecol 1994; 101:1048.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwebke JR. Asymptomatic bacterial vaginosis: Response to therapy. Am J Obstet Gynecol 2000; 183:1434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hillier SL, Lipinski C, Briselden AM, Eschenbach DA. Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis. Obstet Gynecol 1993; 81:963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atashili J, Poole C, Ndumbe PM, et al. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS 2008; 22:1493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen CR, Lingappa JR, Baeten JM, et al. Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. PLoS Med 2012; 9:e1001251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Schalkwyk J, Yudin MH, INFECTIOUS DISEASE COMMITTEE. Vulvovaginitis: screening for and management of trichomoniasis, vulvovaginal candidiasis, and bacterial vaginosis. J Obstet Gynaecol Can 2015; 37:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swedberg J, Steiner JF, Deiss F, et al. Comparison of single-dose vs one-week course of metronidazole for symptomatic bacterial vaginosis. JAMA 1985; 254:1046.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Livengood CH 3rd, Soper DE, Sheehan KL, et al. Comparison of once-daily and twice-daily dosing of 0.75% metronidazole gel in the treatment of bacterial vaginosis. Sex Transm Dis 1999; 26:137.
          </a>
         </li>
         <li class="breakAll">
          METROGEL - metronidazole gel. US Food and Drug Administration (FDA) approved product information. Revised March 2011. US National Library of Medicine. Available at: https://dailymed.nlm.nih.gov/dailymed/index.cfm (Accessed on June 28, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferris DG, Litaker MS, Woodward L, et al. Treatment of bacterial vaginosis: a comparison of oral metronidazole, metronidazole vaginal gel, and clindamycin vaginal cream. J Fam Pract 1995; 41:443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanson JM, McGregor JA, Hillier SL, et al. Metronidazole for bacterial vaginosis. A comparison of vaginal gel vs. oral therapy. J Reprod Med 2000; 45:889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ransom SB, McComish JF, Greenberg R, Tolford DA. Oral metronidazole vs. Metrogel Vaginal for treating bacterial vaginosis. Cost-effectiveness evaluation. J Reprod Med 1999; 44:359.
          </a>
         </li>
         <li class="breakAll">
          NUVESSA- metronidazole gel. US Food and Drug Administration (FDA) approved product information. Revised October, 2021. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on October 27, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwebke JR, Marrazzo J, Beelen AP, Sobel JD. A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Metronidazole Vaginal Gel 1.3% in the Treatment of Bacterial Vaginosis. Sex Transm Dis 2015; 42:376.
          </a>
         </li>
         <li class="breakAll">
          Metronidazole tablet. US Food and Drug Administration (FDA) approved product information. Revised February, 2006. US National Library of Medicine. Available at: https://dailymed.nlm.nih.gov (Accessed on January 27, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mergenhagen KA, Wattengel BA, Skelly MK, et al. Fact versus Fiction: a Review of the Evidence behind Alcohol and Antibiotic Interactions. Antimicrob Agents Chemother 2020; 64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurohara ML, Kwong FK, Lebherz TB, Klaustermeyer WB. Metronidazole hypersensitivity and oral desensitization. J Allergy Clin Immunol 1991; 88:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gendelman SR, Pien LC, Gutta RC, Abouhassan SR. Modified oral metronidazole desensitization protocol. Allergy Rhinol (Providence) 2014; 5:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oduyebo OO, Anorlu RI, Ogunsola FT. The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women. Cochrane Database Syst Rev 2009; :CD006055.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koumans EH, Markowitz LE, Hogan V, CDC BV Working Group. Indications for therapy and treatment recommendations for bacterial vaginosis in nonpregnant and pregnant women: a synthesis of data. Clin Infect Dis 2002; 35:S152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           National guideline for the management of bacterial vaginosis. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). Sex Transm Infect 1999; 75 Suppl 1:S16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joesoef MR, Schmid GP, Hillier SL. Bacterial vaginosis: review of treatment options and potential clinical indications for therapy. Clin Infect Dis 1999; 28 Suppl 1:S57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greaves WL, Chungafung J, Morris B, et al. Clindamycin versus metronidazole in the treatment of bacterial vaginosis. Obstet Gynecol 1988; 72:799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaginitis in Nonpregnant Patients: ACOG Practice Bulletin, Number 215. Obstet Gynecol 2020; 135:e1. Reaffirmed 2022.
          </a>
         </li>
         <li class="breakAll">
          Hillier S, Holmes KK. Bacterial vaginosis. In: Sexually Transmitted Diseases, 2nd ed, Holmes KK, Mardh PA, Sparling PF, Wiesner PJ (Eds), McGraw-Hill, New York 1990. p.547.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joesoef MR, Schmid GP. Bacterial vaginosis: review of treatment options and potential clinical indications for therapy. Clin Infect Dis 1995; 20 Suppl 1:S72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bro F. Metronidazole pessaries compared with placebo in the treatment of bacterial vaginosis. Scand J Prim Health Care 1990; 8:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwebke JR, Desmond RA. A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis. Clin Infect Dis 2007; 44:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 2014; 69:881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paavonen J, Mangioni C, Martin MA, Wajszczuk CP. Vaginal clindamycin and oral metronidazole for bacterial vaginosis: a randomized trial. Obstet Gynecol 2000; 96:256.
          </a>
         </li>
         <li class="breakAll">
          CLINDESSE- clindamycin phosphate cream. US Food and Drug Administration (FDA) approved product information. Revised October 2021. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on January 11, 2022).
         </li>
         <li class="breakAll">
          XACIATO- clindamycin phosphate gel. US Food and Drug Administration (FDA) approved product information. Revised December 2021. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on August 31, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faro S, Skokos CK, Clindesse Investigators Group. The efficacy and safety of a single dose of Clindesse vaginal cream versus a seven-dose regimen of Cleocin vaginal cream in patients with bacterial vaginosis. Infect Dis Obstet Gynecol 2005; 13:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mauck C, Hillier SL, Gendreau J, et al. Single-Dose, Bioadhesive Clindamycin 2% Gel for Bacterial Vaginosis: A Randomized Controlled Trial. Obstet Gynecol 2022; 139:1092.
          </a>
         </li>
         <li class="breakAll">
          Clindesse- clindamycin phosphate cream. US Food and Drug Administration (FDA) approved product information. Revised March, 2020. US National Library of Medicine. Available at: https://dailymed.nlm.nih.gov/dailymed/ (Accessed on June 28, 2021).
         </li>
         <li class="breakAll">
          Clindamycin hydrochloride. US Food and Drug Administration (FDA) approved product information. Revised March, 2020. US National Library of Medicine. Available at: https://dailymed.nlm.nih.gov/dailymed/ (Accessed on June 28, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beigi RH, Austin MN, Meyn LA, et al. Antimicrobial resistance associated with the treatment of bacterial vaginosis. Am J Obstet Gynecol 2004; 191:1124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tinidazole (Tindamax)--a new option for treatment of bacterial vaginosis. Med Lett Drugs Ther 2007; 49:73.
          </a>
         </li>
         <li class="breakAll">
          Tinidazole tablet. US Food and Drug Administration (FDA) approved product information. Revised January, 2022. US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/ (Accessed on August 03, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Livengood CH 3rd, Ferris DG, Wiesenfeld HC, et al. Effectiveness of two tinidazole regimens in treatment of bacterial vaginosis: a randomized controlled trial. Obstet Gynecol 2007; 110:302.
          </a>
         </li>
         <li class="breakAll">
          Tinidazole tablet. US Food and Drug Administration (FDA) approved product information. Revised Dec, 2019. US National Library of Medicine. Available at: https://dailymed.nlm.nih.gov/dailymed/ (Accessed on April 30, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ekgren J, Norling BK, Degre M, Midtvedt T. Comparison of tinidazole given as a single dose and on 2 consecutive days for the treatment of nonspecific bacterial vaginosis. Gynecol Obstet Invest 1988; 26:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schindler EM, Thamm H, Ansmann EB, et al. [Treatment of bacterial vaginitis. Multicenter, randomized, open study with tinidazole in comparison with metronidazole]. Fortschr Med 1991; 109:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwebke JR, Desmond RA. Tinidazole vs metronidazole for the treatment of bacterial vaginosis. Am J Obstet Gynecol 2011; 204:211.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milani M, Barcellona E, Agnello A. Efficacy of the combination of 2 g oral tinidazole and acidic buffering vaginal gel in comparison with vaginal clindamycin alone in bacterial vaginosis: a randomized, investigator-blinded, controlled trial. Eur J Obstet Gynecol Reprod Biol 2003; 109:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwebke JR, Morgan FG Jr, Koltun W, Nyirjesy P. A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis. Am J Obstet Gynecol 2017; 217:678.e1.
          </a>
         </li>
         <li class="breakAll">
          Secnidasole oral granules. US Food and Drug Administration (FDA) approved product information. Revised September 2017. US National Library of Medicine. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209363s015lbl.pdf (Accessed on June 17, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Núñez JT, Gómez G. Low-dose secnidazole in the treatment of bacterial vaginosis. Int J Gynaecol Obstet 2005; 88:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hillier SL, Nyirjesy P, Waldbaum AS, et al. Secnidazole Treatment of Bacterial Vaginosis: A Randomized Controlled Trial. Obstet Gynecol 2017; 130:379.
          </a>
         </li>
         <li class="breakAll">
          Dequalinium chloride. Health Canada approved product monograph. Revised Sept, 2021. Health Canada. https://pdf.hres.ca/dpd_pm/00063156.PDF (Accessed on October 25, 2022).
         </li>
         <li class="breakAll">
          Dequalinium chloride. European Medicines Agency (EMA) Summary of product characteristics. Last updated Oct, 2022. European Medicines Agency. https://www.ema.europa.eu/en (Accessed on October 25, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weissenbacher ER, Donders G, Unzeitig V, et al. A comparison of dequalinium chloride vaginal tablets (Fluomizin®) and clindamycin vaginal cream in the treatment of bacterial vaginosis: a single-blind, randomized clinical trial of efficacy and safety. Gynecol Obstet Invest 2012; 73:8.
          </a>
         </li>
         <li class="breakAll">
          Sobel J, Wayne State University School of Medicine, 2023, personal communication.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Senok AC, Verstraelen H, Temmerman M, Botta GA. Probiotics for the treatment of bacterial vaginosis. Cochrane Database Syst Rev 2009; :CD006289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falagas M, Betsi GI, Athanasiou S. Probiotics for the treatment of women with bacterial vaginosis. Clin Microbiol Infect 2007; 13:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen CR, Wierzbicki MR, French AL, et al. Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis. N Engl J Med 2020; 382:1906.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration. MedWatch safety alerts for human medical products. Available at: https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ (Accessed on November 13, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marrazzo JM, Dombrowski JC, Wierzbicki MR, et al. Safety and Efficacy of a Novel Vaginal Anti-infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-blind, Phase 2, Controlled Trial. Clin Infect Dis 2019; 68:803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCormack WM, Covino JM, Thomason JL, et al. Comparison of clindamycin phosphate vaginal cream with triple sulfonamide vaginal cream in the treatment of bacterial vaginosis. Sex Transm Dis 2001; 28:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wathne B, Holst E, Hovelius B, Mårdh PA. Erythromycin versus metronidazole in the treatment of bacterial vaginosis. Acta Obstet Gynecol Scand 1993; 72:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piot P. Bacterial vaginosis. An evaluation of treatment. Scand J Urol Nephrol Suppl 1984; 86:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wewalka G, Stary A, Bosse B, et al. Efficacy of povidone-iodine vaginal suppositories in the treatment of bacterial vaginosis. Dermatology 2002; 204 Suppl 1:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duff P, Lee ML, Hillier SL, et al. Amoxicillin treatment of bacterial vaginosis during pregnancy. Obstet Gynecol 1991; 77:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schoeman J, Steyn PS, Odendaal HJ, Grové D. Bacterial vaginosis diagnosed at the first antenatal visit better predicts preterm labour than diagnosis later in pregnancy. J Obstet Gynaecol 2005; 25:751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verstraelen H, Verhelst R, Roelens K, Temmerman M. Antiseptics and disinfectants for the treatment of bacterial vaginosis: a systematic review. BMC Infect Dis 2012; 12:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradshaw CS, Vodstrcil LA, Hocking JS, et al. Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use. Clin Infect Dis 2013; 56:777.
          </a>
         </li>
         <li class="breakAll">
          European (International Union against Sexually Transmitted Infections [IUSTI]/World Health Organization [WHO]) guideline on the management of vaginal discharge, 2011. Available at: http://journals.sagepub.com/doi/pdf/10.1258/ijsa.2011.011012 (Accessed on June 15, 2017).
         </li>
         <li class="breakAll">
          UK national guideline for the management of bacterial vaginosis, 2012. Available at: https://www.bashh.org/documents/4413.pdf (Accessed on June 15, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev 2013; :CD000262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonald HM, O'Loughlin JA, Vigneswaran R, et al. Impact of metronidazole therapy on preterm birth in women with bacterial vaginosis flora (Gardnerella vaginalis): a randomised, placebo controlled trial. Br J Obstet Gynaecol 1997; 104:1391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morales WJ, Schorr S, Albritton J. Effect of metronidazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis: a placebo-controlled, double-blind study. Am J Obstet Gynecol 1994; 171:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hauth JC, Goldenberg RL, Andrews WW, et al. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N Engl J Med 1995; 333:1732.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bretelle F, Fenollar F, Baumstarck K, et al. Screen-and-treat program by point-of-care of Atopobium vaginae and Gardnerella vaginalis in preventing preterm birth (AuTop trial): study protocol for a randomized controlled trial. Trials 2015; 16:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bretelle F, Loubiere S, Desbriere R. Effectiveness and Costs of Molecular Screening and Treatment for Bacterial Vaginosis to Prevent Preterm Birth The AuTop Randomized Clinical Trial. JAMA Pediatr 2023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leitich H, Brunbauer M, Bodner-Adler B, et al. Antibiotic treatment of bacterial vaginosis in pregnancy: a meta-analysis. Am J Obstet Gynecol 2003; 188:752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okun N, Gronau KA, Hannah ME. Antibiotics for bacterial vaginosis or Trichomonas vaginalis in pregnancy: A systematic review. Obstet Gynecol 2005; 105:857.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guise JM, Mahon SM, Aickin M, et al. Screening for bacterial vaginosis in pregnancy. Am J Prev Med 2001; 20:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riggs MA, Klebanoff MA. Treatment of vaginal infections to prevent preterm birth: a meta-analysis. Clin Obstet Gynecol 2004; 47:796.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joesoef MR, Hillier SL, Wiknjosastro G, et al. Intravaginal clindamycin treatment for bacterial vaginosis: effects on preterm delivery and low birth weight. Am J Obstet Gynecol 1995; 173:1527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ugwumadu A, Reid F, Hay P, Manyonda I. Natural history of bacterial vaginosis and intermediate flora in pregnancy and effect of oral clindamycin. Obstet Gynecol 2004; 104:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yudin MH, Landers DV, Meyn L, Hillier SL. Clinical and cervical cytokine response to treatment with oral or vaginal metronidazole for bacterial vaginosis during pregnancy: a randomized trial. Obstet Gynecol 2003; 102:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lamont RF, Nhan-Chang CL, Sobel JD, et al. Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and metaanalysis. Am J Obstet Gynecol 2011; 205:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caro-Patón T, Carvajal A, Martin de Diego I, et al. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol 1997; 44:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burtin P, Taddio A, Ariburnu O, et al. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol 1995; 172:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheehy O, Santos F, Ferreira E, Berard A. The use of metronidazole during pregnancy: a review of evidence. Curr Drug Saf 2015; 10:170.
          </a>
         </li>
         <li class="breakAll">
          Drugs in pregnancy and lacatation: a reference guide to fetal and neonatal risk, 11, Briggs GC (Ed), Wolters Kluwer, Philadelphia, PA 2017.
         </li>
         <li class="breakAll">
          LactMed. Available at: https://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm (Accessed on June 15, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soper DE. Bacterial vaginosis and surgical site infections. Am J Obstet Gynecol 2020; 222:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ACOG Practice Bulletin No. 195: Prevention of Infection After Gynecologic Procedures. Obstet Gynecol 2018; 131:e172. Reaffirmed 2022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muzny CA, Schwebke JR. Asymptomatic Bacterial Vaginosis: To Treat or Not to Treat? Curr Infect Dis Rep 2020; 22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Penney GC, Thomson M, Norman J, et al. A randomised comparison of strategies for reducing infective complications of induced abortion. Br J Obstet Gynaecol 1998; 105:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larsson PG, Platz-Christensen JJ, Dalaker K, et al. Treatment with 2% clindamycin vaginal cream prior to first trimester surgical abortion to reduce signs of postoperative infection: a prospective, double-blinded, placebo-controlled, multicenter study. Acta Obstet Gynecol Scand 2000; 79:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller L, Thomas K, Hughes JP, et al. Randomised treatment trial of bacterial vaginosis to prevent post-abortion complication. BJOG 2004; 111:982.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crowley T, Low N, Turner A, et al. Antibiotic prophylaxis to prevent post-abortal upper genital tract infection in women with bacterial vaginosis: randomised controlled trial. BJOG 2001; 108:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larsson PG, Platz-Christensen JJ, Thejls H, et al. Incidence of pelvic inflammatory disease after first-trimester legal abortion in women with bacterial vaginosis after treatment with metronidazole: a double-blind, randomized study. Am J Obstet Gynecol 1992; 166:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caddy S, Yudin MH, Hakim J, et al. Best practices to minimize risk of infection with intrauterine device insertion. J Obstet Gynaecol Can 2014; 36:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwebke JR, Desmond R. A randomized trial of metronidazole in asymptomatic bacterial vaginosis to prevent the acquisition of sexually transmitted diseases. Am J Obstet Gynecol 2007; 196:517.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wawer MJ, Sewankambo NK, Serwadda D, et al. Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group. Lancet 1999; 353:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grosskurth H, Mosha F, Todd J, et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet 1995; 346:530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moreira C, Venkatesh KK, DeLong A, et al. Effect of treatment of asymptomatic bacterial vaginosis on HIV-1 shedding in the genital tract among women on antiretroviral therapy: a pilot study. Clin Infect Dis 2009; 49:991.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nygren P, Fu R, Freeman M, et al. Evidence on the benefits and harms of screening and treating pregnant women who are asymptomatic for bacterial vaginosis: an update review for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 148:220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Committee on Practice Bulletins—Obstetrics, The American College of Obstetricians and Gynecologists. Practice bulletin no. 130: prediction and prevention of preterm birth. Obstet Gynecol 2012; 120:964. Reaffirmed 2018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yudin MH, Money DM, Infectious Diseases Committee. Screening and management of bacterial vaginosis in pregnancy. J Obstet Gynaecol Can 2008; 30:702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           US Preventive Services Task Force, Owens DK, Davidson KW, et al. Screening for Bacterial Vaginosis in Pregnant Persons to Prevent Preterm Delivery: US Preventive Services Task Force Recommendation Statement. JAMA 2020; 323:1286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leitich H, Bodner-Adler B, Brunbauer M, et al. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. Am J Obstet Gynecol 2003; 189:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           U.S. Preventive Services Task Force. Screening for bacterial vaginosis in pregnancy to prevent preterm delivery: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 148:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ugwumadu A, Manyonda I, Reid F, Hay P. Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial. Lancet 2003; 361:983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lamont RF, Duncan SL, Mandal D, Bassett P. Intravaginal clindamycin to reduce preterm birth in women with abnormal genital tract flora. Obstet Gynecol 2003; 101:516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macones GA, Parry S, Elkousy M, et al. A polymorphism in the promoter region of TNF and bacterial vaginosis: preliminary evidence of gene-environment interaction in the etiology of spontaneous preterm birth. Am J Obstet Gynecol 2004; 190:1504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klebanoff MA, Hillier SL, Nugent RP, et al. Is bacterial vaginosis a stronger risk factor for preterm birth when it is diagnosed earlier in gestation? Am J Obstet Gynecol 2005; 192:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leitich H, Kiss H. Asymptomatic bacterial vaginosis and intermediate flora as risk factors for adverse pregnancy outcome. Best Pract Res Clin Obstet Gynaecol 2007; 21:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eschenbach DA. Bacterial vaginosis: emphasis on upper genital tract complications. Obstet Gynecol Clin North Am 1989; 16:593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hillier SL, Martius J, Krohn M, et al. A case-control study of chorioamnionic infection and histologic chorioamnionitis in prematurity. N Engl J Med 1988; 319:972.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thinkhamrop J, Hofmeyr GJ, Adetoro O, et al. Antibiotic prophylaxis during the second and third trimester to reduce adverse pregnancy outcomes and morbidity. Cochrane Database Syst Rev 2015; :CD002250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Odendaal HJ, Popov I, Schoeman J, et al. Preterm labour--is bacterial vaginosis involved? S Afr Med J 2002; 92:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klebanoff MA, Carey JC, Hauth JC, et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med 2001; 345:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vermeulen GM, Bruinse HW. Prophylactic administration of clindamycin 2% vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk: a randomised placebo-controlled double-blind trial. Br J Obstet Gynaecol 1999; 106:652.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amaya-Guio J, Viveros-Carreño DA, Sierra-Barrios EM, et al. Antibiotic treatment for the sexual partners of women with bacterial vaginosis. Cochrane Database Syst Rev 2016; 10:CD011701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Potter J. Should sexual partners of women with bacterial vaginosis receive treatment? Br J Gen Pract 1999; 49:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwebke JR, Lensing SY, Lee J, et al. Treatment of Male Sexual Partners of Women With Bacterial Vaginosis: A Randomized, Double-Blind, Placebo-Controlled Trial. Clin Infect Dis 2021; 73:e672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradshaw CS, Walker SM, Vodstrcil LA, et al. The influence of behaviors and relationships on the vaginal microbiota of women and their female partners: the WOW Health Study. J Infect Dis 2014; 209:1562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jain A, Bradbeer C. A case of successful management of recurrent bacterial vaginosis of neovagina after male to female gender reassignment surgery. Int J STD AIDS 2007; 18:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Birse KD, Kratzer K, Zuend CF, et al. The neovaginal microbiome of transgender women post-gender reassignment surgery. Microbiome 2020; 8:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marrazzo JM, Thomas KK, Ringwood K. A behavioural intervention to reduce persistence of bacterial vaginosis among women who report sex with women: results of a randomised trial. Sex Transm Infect 2011; 87:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plummer EL, Sfameni AM, Vodstrcil LA, et al. Prevotella and Gardnerella Are Associated With Treatment Failure Following First-line Antibiotics for Bacterial Vaginosis. J Infect Dis 2023; 228:646.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mollin A, Katta M, Sobel JD, Akins RA. Association of key species of vaginal bacteria of recurrent bacterial vaginosis patients before and after oral metronidazole therapy with short- and long-term clinical outcomes. PLoS One 2022; 17:e0272012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swidsinski A, Mendling W, Loening-Baucke V, et al. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol 2008; 198:97.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verwijs MC, Agaba SK, Darby AC, van de Wijgert JHHM. Impact of oral metronidazole treatment on the vaginal microbiota and correlates of treatment failure. Am J Obstet Gynecol 2020; 222:157.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sobel JD, Ferris D, Schwebke J, et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol 2006; 194:1283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gray RH, Kigozi G, Serwadda D, et al. The effects of male circumcision on female partners' genital tract symptoms and vaginal infections in a randomized trial in Rakai, Uganda. Am J Obstet Gynecol 2009; 200:42.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradshaw CS, Morton AN, Hocking J, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis 2006; 193:1478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Surapaneni S, Akins R, Sobel JD. Recurrent Bacterial Vaginosis: An Unmet Therapeutic Challenge. Experience With a Combination Pharmacotherapy Long-Term Suppressive Regimen. Sex Transm Dis 2021; 48:761.
          </a>
         </li>
         <li class="breakAll">
          Barbieri R, Harvard Medical School, Harvard University, 2021, personal communication.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Powell AM, Nyirjesy P. Recurrent vulvovaginitis. Best Pract Res Clin Obstet Gynaecol 2014; 28:967.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson J. Managing recurrent bacterial vaginosis. Sex Transm Infect 2004; 80:8.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 113103 Version 49.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34292926" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Sexually Transmitted Infections Treatment Guidelines, 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34292926" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Sexually Transmitted Infections Treatment Guidelines, 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14981375" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Time course of the regression of asymptomatic bacterial vaginosis in pregnancy with and without treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7826957" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : A longitudinal study of bacterial vaginosis during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11120507" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Asymptomatic bacterial vaginosis: Response to therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8497364" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18614873" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22745608" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26001874" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Vulvovaginitis: screening for and management of trichomoniasis, vulvovaginal candidiasis, and bacterial vaginosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3894707" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Comparison of single-dose vs one-week course of metronidazole for symptomatic bacterial vaginosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10100770" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Comparison of once-daily and twice-daily dosing of 0.75% metronidazole gel in the treatment of bacterial vaginosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10100770" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Comparison of once-daily and twice-daily dosing of 0.75% metronidazole gel in the treatment of bacterial vaginosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7595261" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Treatment of bacterial vaginosis: a comparison of oral metronidazole, metronidazole vaginal gel, and clindamycin vaginal cream.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11127100" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Metronidazole for bacterial vaginosis. A comparison of vaginal gel vs. oral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10319306" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Oral metronidazole vs. Metrogel Vaginal for treating bacterial vaginosis. Cost-effectiveness evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10319306" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Oral metronidazole vs. Metrogel Vaginal for treating bacterial vaginosis. Cost-effectiveness evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26222750" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Metronidazole Vaginal Gel 1.3% in the Treatment of Bacterial Vaginosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26222750" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Metronidazole Vaginal Gel 1.3% in the Treatment of Bacterial Vaginosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31871085" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Fact versus Fiction: a Review of the Evidence behind Alcohol and Antibiotic Interactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1880329" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Metronidazole hypersensitivity and oral desensitization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24612959" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Modified oral metronidazole desensitization protocol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19588379" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12353202" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Indications for therapy and treatment recommendations for bacterial vaginosis in nonpregnant and pregnant women: a synthesis of data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10616375" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : National guideline for the management of bacterial vaginosis. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10028110" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Bacterial vaginosis: review of treatment options and potential clinical indications for therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3050654" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Clindamycin versus metronidazole in the treatment of bacterial vaginosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31856123" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Vaginitis in Nonpregnant Patients: ACOG Practice Bulletin, Number 215.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31856123" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Vaginitis in Nonpregnant Patients: ACOG Practice Bulletin, Number 215.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7795111" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Bacterial vaginosis: review of treatment options and potential clinical indications for therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2284521" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Metronidazole pessaries compared with placebo in the treatment of bacterial vaginosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17173219" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24324224" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10908773" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Vaginal clindamycin and oral metronidazole for bacterial vaginosis: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10908773" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Vaginal clindamycin and oral metronidazole for bacterial vaginosis: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10908773" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Vaginal clindamycin and oral metronidazole for bacterial vaginosis: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16240515" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The efficacy and safety of a single dose of Clindesse vaginal cream versus a seven-dose regimen of Cleocin vaginal cream in patients with bacterial vaginosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35675606" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Single-Dose, Bioadhesive Clindamycin 2% Gel for Bacterial Vaginosis: A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35675606" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Single-Dose, Bioadhesive Clindamycin 2% Gel for Bacterial Vaginosis: A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35675606" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Single-Dose, Bioadhesive Clindamycin 2% Gel for Bacterial Vaginosis: A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15507930" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Antimicrobial resistance associated with the treatment of bacterial vaginosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17848905" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Tinidazole (Tindamax)--a new option for treatment of bacterial vaginosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17848905" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Tinidazole (Tindamax)--a new option for treatment of bacterial vaginosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17666604" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Effectiveness of two tinidazole regimens in treatment of bacterial vaginosis: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17666604" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Effectiveness of two tinidazole regimens in treatment of bacterial vaginosis: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3068098" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Comparison of tinidazole given as a single dose and on 2 consecutive days for the treatment of nonspecific bacterial vaginosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2045037" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : [Treatment of bacterial vaginitis. Multicenter, randomized, open study with tinidazole in comparison with metronidazole].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21167471" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Tinidazole vs metronidazole for the treatment of bacterial vaginosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12818447" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Efficacy of the combination of 2 g oral tinidazole and acidic buffering vaginal gel in comparison with vaginal clindamycin alone in bacterial vaginosis: a randomized, investigator-blinded, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28867602" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28867602" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15733882" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Low-dose secnidazole in the treatment of bacterial vaginosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28697102" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Secnidazole Treatment of Bacterial Vaginosis: A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28697102" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Secnidazole Treatment of Bacterial Vaginosis: A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28697102" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Secnidazole Treatment of Bacterial Vaginosis: A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22205034" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : A comparison of dequalinium chloride vaginal tablets (Fluomizin®) and clindamycin vaginal cream in the treatment of bacterial vaginosis: a single-blind, randomized clinical trial of efficacy and safety.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22205034" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : A comparison of dequalinium chloride vaginal tablets (Fluomizin®) and clindamycin vaginal cream in the treatment of bacterial vaginosis: a single-blind, randomized clinical trial of efficacy and safety.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19821358" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Probiotics for the treatment of bacterial vaginosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17633390" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Probiotics for the treatment of women with bacterial vaginosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32402161" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32402161" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30184181" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Safety and Efficacy of a Novel Vaginal Anti-infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-blind, Phase 2, Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11689755" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Comparison of clindamycin phosphate vaginal cream with triple sulfonamide vaginal cream in the treatment of bacterial vaginosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8394627" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Erythromycin versus metronidazole in the treatment of bacterial vaginosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6336137" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Bacterial vaginosis. An evaluation of treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12011527" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Efficacy of povidone-iodine vaginal suppositories in the treatment of bacterial vaginosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1992412" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Amoxicillin treatment of bacterial vaginosis during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16368577" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Bacterial vaginosis diagnosed at the first antenatal visit better predicts preterm labour than diagnosis later in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22742642" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Antiseptics and disinfectants for the treatment of bacterial vaginosis: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23243173" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23243173" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23243173" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23440777" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Antibiotics for treating bacterial vaginosis in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9422018" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Impact of metronidazole therapy on preterm birth in women with bacterial vaginosis flora (Gardnerella vaginalis): a randomised, placebo controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8059811" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Effect of metronidazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis: a placebo-controlled, double-blind study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7491136" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26482128" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Screen-and-treat program by point-of-care of Atopobium vaginae and Gardnerella vaginalis in preventing preterm birth (AuTop trial): study protocol for a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Effectiveness and Costs of Molecular Screening and Treatment for Bacterial Vaginosis to Prevent Preterm Birth The AuTop Randomized Clinical Trial
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12634652" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Antibiotic treatment of bacterial vaginosis in pregnancy: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15802417" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Antibiotics for bacterial vaginosis or Trichomonas vaginalis in pregnancy: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11306234" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Screening for bacterial vaginosis in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15596934" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Treatment of vaginal infections to prevent preterm birth: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7503196" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Intravaginal clindamycin treatment for bacterial vaginosis: effects on preterm delivery and low birth weight.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15229009" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Natural history of bacterial vaginosis and intermediate flora in pregnancy and effect of oral clindamycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12962937" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Clinical and cervical cytokine response to treatment with oral or vaginal metronidazole for bacterial vaginosis during pregnancy: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22071048" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and metaanalysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9278206" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Is metronidazole teratogenic? A meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7856680" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Safety of metronidazole in pregnancy: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25986038" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : The use of metronidazole during pregnancy: a review of evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25986038" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : The use of metronidazole during pregnancy: a review of evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25986038" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : The use of metronidazole during pregnancy: a review of evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31499057" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Bacterial vaginosis and surgical site infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29794678" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : ACOG Practice Bulletin No. 195: Prevention of Infection After Gynecologic Procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33814990" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Asymptomatic Bacterial Vaginosis: To Treat or Not to Treat?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9647149" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : A randomised comparison of strategies for reducing infective complications of induced abortion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10830767" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Treatment with 2% clindamycin vaginal cream prior to first trimester surgical abortion to reduce signs of postoperative infection: a prospective, double-blinded, placebo-controlled, multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15327614" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Randomised treatment trial of bacterial vaginosis to prevent post-abortion complication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11305547" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Antibiotic prophylaxis to prevent post-abortal upper genital tract infection in women with bacterial vaginosis: randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1733176" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Incidence of pelvic inflammatory disease after first-trimester legal abortion in women with bacterial vaginosis after treatment with metronidazole: a double-blind, randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24612897" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Best practices to minimize risk of infection with intrauterine device insertion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17547876" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : A randomized trial of metronidazole in asymptomatic bacterial vaginosis to prevent the acquisition of sexually transmitted diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10028980" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7658778" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19694541" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Effect of treatment of asymptomatic bacterial vaginosis on HIV-1 shedding in the genital tract among women on antiretroviral therapy: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18252684" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Evidence on the benefits and harms of screening and treating pregnant women who are asymptomatic for bacterial vaginosis: an update review for the U.S. Preventive Services Task Force.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22996126" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Practice bulletin no. 130: prediction and prevention of preterm birth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18786293" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Screening and management of bacterial vaginosis in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32259236" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Screening for Bacterial Vaginosis in Pregnant Persons to Prevent Preterm Delivery: US Preventive Services Task Force Recommendation Statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12861153" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18252683" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Screening for bacterial vaginosis in pregnancy to prevent preterm delivery: U.S. Preventive Services Task Force recommendation statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12660054" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12636956" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Intravaginal clindamycin to reduce preterm birth in women with abnormal genital tract flora.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15284722" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : A polymorphism in the promoter region of TNF and bacterial vaginosis: preliminary evidence of gene-environment interaction in the etiology of spontaneous preterm birth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15695989" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Is bacterial vaginosis a stronger risk factor for preterm birth when it is diagnosed earlier in gestation?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17241817" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Asymptomatic bacterial vaginosis and intermediate flora as risk factors for adverse pregnancy outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2687747" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Bacterial vaginosis: emphasis on upper genital tract complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3262199" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : A case-control study of chorioamnionic infection and histologic chorioamnionitis in prematurity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26092137" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Antibiotic prophylaxis during the second and third trimester to reduce adverse pregnancy outcomes and morbidity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12040953" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Preterm labour--is bacterial vaginosis involved?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11519502" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10428520" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Prophylactic administration of clindamycin 2% vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk: a randomised placebo-controlled double-blind trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27696372" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Antibiotic treatment for the sexual partners of women with bacterial vaginosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10818662" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Should sexual partners of women with bacterial vaginosis receive treatment?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33383580" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Treatment of Male Sexual Partners of Women With Bacterial Vaginosis: A Randomized, Double-Blind, Placebo-Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24285846" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : The influence of behaviors and relationships on the vaginal microbiota of women and their female partners: the WOW Health Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17331294" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : A case of successful management of recurrent bacterial vaginosis of neovagina after male to female gender reassignment surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32370783" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : The neovaginal microbiome of transgender women post-gender reassignment surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21653935" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : A behavioural intervention to reduce persistence of bacterial vaginosis among women who report sex with women: results of a randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37427495" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Prevotella and Gardnerella Are Associated With Treatment Failure Following First-line Antibiotics for Bacterial Vaginosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35901180" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Association of key species of vaginal bacteria of recurrent bacterial vaginosis patients before and after oral metronidazole therapy with short- and long-term clinical outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18005928" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31404542" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Impact of oral metronidazole treatment on the vaginal microbiota and correlates of treatment failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16647911" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18976733" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : The effects of male circumcision on female partners' genital tract symptoms and vaginal infections in a randomized trial in Rakai, Uganda.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16652274" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34110746" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Recurrent Bacterial Vaginosis: An Unmet Therapeutic Challenge. Experience With a Combination Pharmacotherapy Long-Term Suppressive Regimen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34110746" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Recurrent Bacterial Vaginosis: An Unmet Therapeutic Challenge. Experience With a Combination Pharmacotherapy Long-Term Suppressive Regimen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25220102" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Recurrent vulvovaginitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14755028" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Managing recurrent bacterial vaginosis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
